State Street Corp Purchases 183,400 Shares of Stryker Corporation $SYK

State Street Corp grew its position in Stryker Corporation (NYSE:SYK) by 1.2% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 15,532,565 shares of the medical technology company’s stock after acquiring an additional 183,400 shares during the period. State Street Corp’s holdings in Stryker were worth $4,903,772,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in Stryker by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after acquiring an additional 69,851 shares during the period. Wellington Management Group LLP raised its position in shares of Stryker by 0.6% during the second quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock worth $2,571,357,000 after purchasing an additional 45,478 shares during the period. Norges Bank bought a new position in shares of Stryker during the 4th quarter valued at about $1,822,272,000. Bank of America Corp DE bought a new position in shares of Stryker during the 2nd quarter valued at about $1,404,284,000. Finally, Royal Bank of Canada grew its position in shares of Stryker by 6.5% in the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after purchasing an additional 199,863 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. BTIG Research dropped their target price on shares of Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Citigroup lowered their price objective on shares of Stryker from $399.00 to $360.00 and set a “buy” rating for the company in a research report on Thursday, September 10th. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Finally, Evercore set a $350.00 target price on shares of Stryker in a research note on Monday, July 6th. Eighteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $374.42.

Stryker Stock Up 0.9%

Shares of NYSE:SYK traded up $2.52 during midday trading on Tuesday, reaching $276.71. The company had a trading volume of 635,307 shares, compared to its average volume of 2,434,301. Stryker Corporation has a 1-year low of $267.00 and a 1-year high of $392.55. The stock has a market cap of $106.14 billion, a PE ratio of 28.70, a P/E/G ratio of 1.74 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average price is $318.75 and its 200 day moving average price is $321.61.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts forecast that Stryker Corporation will post 15 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.3%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Insider Activity at Stryker

In related news, Director Ronda Stryker sold 300,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the transaction, the director directly owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Debra King sold 826 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is owned by corporate insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.